has anyone died from compounded semaglutide Novo Nordisk tackles harm Ozempic fakes with global authorities Millions are trying FDA-authorized alternatives

These entrants are leveraging strengths in peptide synthesis, low-cost biologics manufacturing, and regulatory agility to shorten development cycles and undercut price points, potentially halving or even reducing cost to one-tenth of current therapy levels

Key takeaways Chinas GLP-1 market is booming, driven by rising diabetes and obesity prevalence, expanded indications (e.g., MASH, CKD, Alzheimers), policy support and momentum from global leaders and innovative local players

The finding that individuals with more pronounced external eating tendencies benefited more from this treatment suggests that its potential to alter unhealthy eating patterns before adverse health conditions develop warrants further exploration

Implications for Treatment Persistence and Outcomes Taken together, discontinuations and interruptions in GLP-1RA use were common in this cohort, particularly during the first year of treatment